Results 21 to 30 of about 12,986,553 (373)

Factor Xa Inhibitor

Japanese Journal of Thrombosis and Hemostasis, 2003
Takashi Koizumi, Masahiko Uchida
openalex   +3 more sources

Andexanet alfa in patients with factor Xa inhibitor-associated intracranial hemorrhage: The prospective observational multicenter ASTRO-DE study. [PDF]

Int J Stroke
Diener HC, Kuklik N, Hüsing A, Alonso A, Nabavi DG, Poli S, Gabriel MM, Maier IL, Grans J.   +8 more
europepmc   +2 more sources

Non-vitamin K oral antagonist failure and tailored treatment in patients with atrial fibrillation and stroke [PDF]

Precision and Future Medicine, 2020
In case of any embolic event, treatment strategy should be established according to the pathomechanisms of failure of non-vitamin K oral anticoagulants (NOAC). A 72-year-old man was referred to our hospital with a sudden speech disturbance.
Hyung Jun Kim, Soyoun Choi, Hee-Jin Kim, Oh Young Bang   +3 more
doaj   +1 more source

Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation. [PDF]

Clin Pharmacol Ther
Lin SY, Liu YB, Ho LT, Kuo CH, Peng YF, Huang CF, Tang SC, Jeng JS.   +7 more
europepmc   +3 more sources

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Circulation, 2023
Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b ...
T. Milling, S. Middeldorp, Lizhen Xu, Bruce R Koch, A. Demchuk, J. Eikelboom, P. Verhamme, A. Cohen, J. Beyer-Westendorf, C. Michael Gibson, J. López-Sendón, M. Crowther, A. Shoamanesh, M. Coppens, Jeannot Schmidt, P. Albaladéjo, S. Connolly, R. Anand, A. Bastani, C. Clark, M. Concha, J. Cornell, K. Dombrowski, G. Fermann, J. Fulmer, J. Goldstein, D. Kereiakes, T. Milling, D. Pallin, N. Patel, M. Refaai, M. Rehman, A. Schmaier, E. Schwarz, W. Shillinglaw, M. Spohn, T. Takata, A. Venkat, J. Welker, I. Welsby, J. Wilson, L. Van Keer, F. Verschuren, M. Blostein, J. Eikelboom, K. Althaus, J. Berrouschot, G. Braun, T. Doeppner, R. Dziewas, S. Genth‐Zotz, P. Greinacher, F. Hamann, F. Hanses, W. Heide, B. Kallmuenzer, P. Kermer, S. Poli, G. Royl, S. Schellong, S. Schnupp, J. Schwarze, C. Spies, G. Thomalla, M. von Mering, K. Weissenborn, F. Wollenweber, C. Gumbinger, U. Jaschinski, M. Maschke, H. Mochmann, W. Pfeilschifter, C. Pohlmann, R. Zahn, P. Bouzat, J. Schmidt, C. Vallejo, B. Floccard, M. Coppens, S. V. van Wissen, E. Arellano-Rodrigo, E. Vallès, R. Alikhan, K. Breen, R. Hall, M. Crowther, P. Albaladéjo, A. Cohen, A. Demchuk, D. Wyse, D. A. Garcia, M. Prins, J. Nakamya, H. Büller, K. Mahaffey, J. Alexander, J. Cairns, R. Hart, C. Joyner, G. Raskob, S. Schulman, R. Veltkamp, B. Meeks, E. Zotova, Sahar Ahmad, T. Pinto, K. Baker, A. Dykstra, I. Holadyk-Gris, Antonio Malvaso   +109 more
semanticscholar   +1 more source

Direct oral anticoagulant: Review article

Journal of Family Medicine and Primary Care, 2022
Venous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year.
Abdulrahman Nasiri, Ahmed AlQahtani, Nora H Rayes, Rawan AlQahtani, Reem Alkharras, Hamad Alghethber   +5 more
doaj   +1 more source

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +1 more source

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study

Frontiers in Medicine, 2022
BackgroundAnti-factor Xa activity has been suggested as a surrogate parameter for judging the effectiveness of pharmacological thromboprophylaxis with low molecular weight heparins in critically ill patients.
Christoph Dibiasi, Christoph Dibiasi, Johannes Gratz, Marion Wiegele, Andreas Baierl, Eva Schaden, Eva Schaden   +6 more
doaj   +1 more source

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +1 more source

The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents

TH Open, 2020
SARS-CoV-2 infection (COVID-19) results in local and systemic activation of inflammation and coagulation. In this review article, we will discuss the potential role of coagulation factor Xa (FXa) in the pathophysiology of COVID-19. FXa, a serine protease,
Galit H. Frydman, Michael B. Streiff, Jean M. Connors, Gregory Piazza   +3 more
doaj   +1 more source